Search…

Shapuaisi (603168.SH) subsidiary receives approval notice for clinical trial of tropisetron hydrochloride eye drops.

05/09/2025

Zhitong Finance and Economics APP News, Shapuaisi (603168.SH) announced that recently, the company's wholly-owned subsidiary, Zhejiang Shapu Health Management Co., Ltd., has obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the Hydrochloride Maoguoquinine Eye Drops (Notice No.: 2025LP02246). The company plans to conduct clinical trials after meeting the conditions.

Latest

2 m ago

Lulu Lemon's Chief Financial Officer stated that the company is currently addressing various challenges, including tariffs.

2 m ago

According to informed sources, Paulson & Co. sold 1.21 million shares of Acadian stock at an average price of $48.15, which is at the bottom of the guidance range of $48.15-50.19.

2 m ago

The German Budget Committee approved the budget for 2025 to pave the way for parliamentary approval.

2 m ago

The German Budget Committee approves the budget for 2025, paving the way for parliamentary approval.

3 m ago

On Thursday, the Bloomberg Electric Vehicle Price Return Index fell by 1.30% to 2986.47 points. Among the components, shares of Japan's Denso Corporation's Tokyo fell by 22.44%, NIO Group's H shares fell by 6.42%, and "Tesla's rival" Rivian, which announced a layoff plan, fell by about 5%, ranking third from the bottom. Among the top three components that rose, the H shares of Ideal Car rose by 0.16%, the Chilean chemical and mining company rose by 1.30%, and Tesla rose by over 1%.

See all latest